Alvotech enters into exclusive licensing agreement with kashiv biosciences for development and commercialization of a proposed biosimilar to xolair® (omalizumab)

Alvotech (nasdaq: alvo), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and kashiv biosciences llc (“kashiv”), a fully integrated biopharmaceutical company, today announced that they have entered into an exclusive licensing agreement for avt23 (also called adl018), a proposed biosimilar to xolair® (omalizumab), which is currently in clinical development.
ALVO Ratings Summary
ALVO Quant Ranking